JP2015218166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015218166A5 JP2015218166A5 JP2015097829A JP2015097829A JP2015218166A5 JP 2015218166 A5 JP2015218166 A5 JP 2015218166A5 JP 2015097829 A JP2015097829 A JP 2015097829A JP 2015097829 A JP2015097829 A JP 2015097829A JP 2015218166 A5 JP2015218166 A5 JP 2015218166A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- expressed
- isoquinoline
- carbonitrile
- dioxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HJHXYSBRTVFEDD-UHFFFAOYSA-N isoquinoline-1-carbonitrile Chemical compound C1=CC=C2C(C#N)=NC=CC2=C1 HJHXYSBRTVFEDD-UHFFFAOYSA-N 0.000 claims 6
- 238000001228 spectrum Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims 5
- 238000005079 FT-Raman Methods 0.000 claims 3
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 208000001076 sarcopenia Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008717 functional decline Effects 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993693P | 2014-05-15 | 2014-05-15 | |
| US61/993,693 | 2014-05-15 | ||
| US201562138037P | 2015-03-25 | 2015-03-25 | |
| US62/138,037 | 2015-03-25 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015218166A JP2015218166A (ja) | 2015-12-07 |
| JP2015218166A5 true JP2015218166A5 (https=) | 2018-06-21 |
| JP6523782B2 JP6523782B2 (ja) | 2019-06-05 |
Family
ID=53276206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015097829A Expired - Fee Related JP6523782B2 (ja) | 2014-05-15 | 2015-05-13 | 新規な結晶性化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9920043B2 (https=) |
| EP (1) | EP3143019B1 (https=) |
| JP (1) | JP6523782B2 (https=) |
| KR (1) | KR101817889B1 (https=) |
| CN (1) | CN106459025B (https=) |
| AU (1) | AU2015260906B2 (https=) |
| CA (1) | CA2891398C (https=) |
| CY (1) | CY1123826T1 (https=) |
| DK (1) | DK3143019T3 (https=) |
| ES (1) | ES2845639T3 (https=) |
| HU (1) | HUE052692T2 (https=) |
| IL (1) | IL248918A0 (https=) |
| MX (1) | MX371014B (https=) |
| PL (1) | PL3143019T3 (https=) |
| PT (1) | PT3143019T (https=) |
| RU (1) | RU2698194C2 (https=) |
| SG (1) | SG11201608320QA (https=) |
| SI (1) | SI3143019T1 (https=) |
| TW (1) | TWI553007B (https=) |
| WO (1) | WO2015173684A1 (https=) |
| ZA (1) | ZA201606796B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201609050UA (en) * | 2014-05-30 | 2016-12-29 | Pfizer | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2023275715A1 (en) * | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089139A2 (en) | 1982-03-16 | 1983-09-21 | Beecham Group Plc | Antibiotics, their preparation and use |
| US4489075A (en) * | 1982-05-15 | 1984-12-18 | Pfizer Inc. | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US20060142387A1 (en) | 2003-06-10 | 2006-06-29 | Rodolfo Cadilla | Chemical compounds |
| MXPA06001751A (es) * | 2003-08-22 | 2006-05-12 | Ligand Pharm Inc | Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno. |
| KR101595238B1 (ko) * | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| MX368898B (es) | 2012-12-03 | 2019-10-21 | Pfizer | Moduladores selectivos del receptor de androgenos novedosos. |
-
2015
- 2015-05-01 AU AU2015260906A patent/AU2015260906B2/en not_active Ceased
- 2015-05-01 HU HUE15726337A patent/HUE052692T2/hu unknown
- 2015-05-01 SI SI201531479T patent/SI3143019T1/sl unknown
- 2015-05-01 US US15/310,570 patent/US9920043B2/en active Active
- 2015-05-01 RU RU2016144671A patent/RU2698194C2/ru active
- 2015-05-01 DK DK15726337.7T patent/DK3143019T3/da active
- 2015-05-01 EP EP15726337.7A patent/EP3143019B1/en not_active Not-in-force
- 2015-05-01 MX MX2016014999A patent/MX371014B/es active IP Right Grant
- 2015-05-01 PL PL15726337.7T patent/PL3143019T3/pl unknown
- 2015-05-01 SG SG11201608320QA patent/SG11201608320QA/en unknown
- 2015-05-01 KR KR1020167031696A patent/KR101817889B1/ko not_active Expired - Fee Related
- 2015-05-01 CN CN201580025357.8A patent/CN106459025B/zh not_active Expired - Fee Related
- 2015-05-01 PT PT157263377T patent/PT3143019T/pt unknown
- 2015-05-01 WO PCT/IB2015/053194 patent/WO2015173684A1/en not_active Ceased
- 2015-05-01 ES ES15726337T patent/ES2845639T3/es active Active
- 2015-05-13 JP JP2015097829A patent/JP6523782B2/ja not_active Expired - Fee Related
- 2015-05-14 TW TW104115438A patent/TWI553007B/zh not_active IP Right Cessation
- 2015-05-14 CA CA2891398A patent/CA2891398C/en active Active
-
2016
- 2016-10-03 ZA ZA2016/06796A patent/ZA201606796B/en unknown
- 2016-11-13 IL IL248918A patent/IL248918A0/en unknown
-
2021
- 2021-02-18 CY CY20211100138T patent/CY1123826T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017142958A (ru) | Кристаллы азабициклического соединения | |
| JP2017531020A5 (https=) | ||
| JP2014506907A5 (https=) | ||
| JP2018520205A5 (https=) | ||
| JP2015512951A5 (https=) | ||
| JP2015511958A5 (https=) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| JP2014507455A5 (https=) | ||
| JP2018024682A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| WO2012042539A3 (en) | 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders | |
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| JP2013543867A5 (https=) | ||
| JP2012521994A5 (https=) | ||
| JP2020519654A5 (https=) | ||
| JP2012526808A5 (https=) | ||
| JP2014530818A5 (https=) | ||
| JP2016510768A5 (https=) | ||
| JP2013522325A5 (https=) | ||
| JP2012533550A5 (https=) | ||
| PH12013501727A1 (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
| JP2018524342A5 (https=) | ||
| JP2019520321A5 (https=) | ||
| JP2010514725A5 (https=) | ||
| JP2020502224A5 (https=) |